143 related articles for article (PubMed ID: 36400666)
21. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.
Dal Pra A; Ghadjar P; Hayoz S; Liu VYT; Spratt DE; Thompson DJS; Davicioni E; Huang HC; Zhao X; Liu Y; Schär C; Gut P; Plasswilm L; Hölscher T; Polat B; Hildebrandt G; Müller AC; Pollack A; Thalmann GN; Zwahlen D; Aebersold DM
Ann Oncol; 2022 Sep; 33(9):950-958. PubMed ID: 35636621
[TBL] [Abstract][Full Text] [Related]
22. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
23. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
Alshalalfa M; Goglia AG; Swami N; Nguyen B; Hougen HY; Khan A; Kishan AU; Punnen S; Nguyen PL; Mahal BA; Dee EC
Urol Oncol; 2023 May; 41(5):253.e21-253.e26. PubMed ID: 37003878
[TBL] [Abstract][Full Text] [Related]
24. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
25. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
[TBL] [Abstract][Full Text] [Related]
26. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
27. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
29. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization.
Fu W; Bubendorf L; Willi N; Moch H; Mihatsch MJ; Sauter G; Gasser TC
Urology; 2000 Nov; 56(5):880-5. PubMed ID: 11068328
[TBL] [Abstract][Full Text] [Related]
30. Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
Mahal BA; Alshalalfa M; Zhao SG; Beltran H; Chen WS; Chipidza F; Davicioni E; Karnes RJ; Ku SY; Lotan TL; Muralidhar V; Rebbeck TR; Schaeffer EM; Spratt DE; Feng FY; Nguyen PL
Cancer; 2020 Apr; 126(7):1407-1412. PubMed ID: 31905251
[TBL] [Abstract][Full Text] [Related]
31. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz B; Schnall M; Schultz D; Cote K; Tomaszewski JE; Wein A
J Urol; 2000 Sep; 164(3 Pt 1):759-63. PubMed ID: 10953141
[TBL] [Abstract][Full Text] [Related]
32. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
Spratt DE; Yousefi K; Deheshi S; Ross AE; Den RB; Schaeffer EM; Trock BJ; Zhang J; Glass AG; Dicker AP; Abdollah F; Zhao SG; Lam LLC; du Plessis M; Choeurng V; Haddad Z; Buerki C; Davicioni E; Weinmann S; Freedland SJ; Klein EA; Karnes RJ; Feng FY
J Clin Oncol; 2017 Jun; 35(18):1991-1998. PubMed ID: 28358655
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
34. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
[TBL] [Abstract][Full Text] [Related]
35. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
36. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
37. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
38. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
[TBL] [Abstract][Full Text] [Related]
39. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
40. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]